Abcellera partners with the governments of canada and british columbia to advance drug development capabilities and infrastructure that will accelerate innovative medicines to patients

Vancouver, british columbia--(business wire)---- $abcl--abcellera (nasdaq: abcl) today announced a ca$701 million co-investment with the governments of canada and british columbia to build new capabilities and infrastructure to develop innovative antibody-based medicines and strengthen canada's leadership in clinical research, manufacturing, and drug development. over the next eight years, abcellera plans to invest ca$401 million in the project, and the governments of canada and british columbia will con.
ABCL Ratings Summary
ABCL Quant Ranking